In clinical settings, angiogenesis‐targeting strategies for gliomas have yielded mixed results, particularly evident in VEGF‐targeting clinical trials where these agents failed to extend patient survival.[28, 29, 30] However, these trials primarily involved patient cohorts with glioblastomas, which are predominantly IDHwt tumors by the nature of the disease. Here, VEGFA is linked to glioma.